Deal Details

Sensorion Completes €60 Million Private Placement

Healthcare

Sensorion private placement

Summary

Sensorion SA (“Sensorion”) (EPA: ALSEN) recently announced a private placement of approximately €60 million (the “Transaction”) with a €20 million strategic investment from Sanofi, and €40 million from existing investors, Redmile Group, Artal, which is advised by Invus, Sofinnova Partners and new leading U.S. healthcare specialist funds, including Cormorant Asset Management, Coastlands Capital and Sphera Healthcare.

Sensorion intends to use the net proceeds from the Transaction to drive the progression of its genetic medicine pipeline, notably SENS-601 (GJB2-GT), by funding key catalysts for the program which targets hearing loss associated with GJB2 mutations, including CTA/IND approval and the enrollment of the first clinical cohort.

Baird served as a placement agent to Sensorion on this Transaction.

About

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. Sensorion is headquartered in Montpellier, France.